NCT04384458 is a NA clinical trial of Hydroxychloroquine in Coronavirus Infections, sponsored by Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara.

What drugs are being tested in NCT04384458?

Interventions in NCT04384458: Hydroxychloroquine, Ivermectin.

What condition does NCT04384458 study?

NCT04384458 studies Coronavirus Infections.

Is NCT04384458 still recruiting?

NCT04384458 is currently status unknown. Last updated 5 October 2020.

Last reviewed 2020-10-05 · How we verify

NCT04384458

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

Status unknown NA Last updated 5 October 2020

What this trial tests

NA trial testing Hydroxychloroquine in Coronavirus Infections in 400 participants. Status unknown.

Timeline

20 July 2020

Primary endpoint
10 September 2020

1 April 2021

Quick facts

Lead sponsor	Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	400
Start date	20 July 2020
Primary completion	10 September 2020
Estimated completion	1 April 2021
Sites	1 location across Brazil

Drugs / interventions tested

Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Ivermectin (ivermectin) — full drug profile →

Conditions studied

Coronavirus Infections — all drugs for Coronavirus Infections →

Sponsor

Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara — full company profile →

Who can join

Adults 18 to 70, any sex, with Coronavirus Infections. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of participants in whom there was a positivity for SARS-CoV-2.
Time frame: Post-intervention at day 52
Proportion of participants in whom there was a a positivity for SARS-CoV-2 through specific examination (RT-PCR) or by serology for antibodies specific (IgM and IgG), corroborated or not with clinical finding of COVID-19, defined as the occurrence of signs and symptoms suggestive of this disease.

Sponsor's own description

We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Zinc and COVID-19: Basis of Current Clinical Trials.
Pal A, Squitti R, Picozza M, Pawar A, et al · · 2021 · cited 95× · PMID 33094446 · DOI 10.1007/s12011-020-02437-9
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
Kaur H, Shekhar N, Sharma S, Sarma P, et al · · 2021 · cited 52× · PMID 33389725 · DOI 10.1007/s43440-020-00195-y
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, et al · · 2021 · cited 48× · PMID 33038449 · DOI 10.1016/j.jconrel.2020.10.009
Potential molecular mechanisms of zinc- and copper-mediated antiviral activity on COVID-19.
Rani I, Goyal A, Bhatnagar M, Manhas S, et al · · 2021 · cited 43× · PMID 34284268 · DOI 10.1016/j.nutres.2021.05.008
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA, Wagstaff KM. · · 2021 · cited 26× · PMID 33341233 · DOI 10.1016/j.bbrc.2020.10.042
Targeting zinc metalloenzymes in coronavirus disease 2019.
Doboszewska U, Wlaź P, Nowak G, Młyniec K. · · 2020 · cited 25× · PMID 32671829 · DOI 10.1111/bph.15199
Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19?
Hecel A, Ostrowska M, Stokowa-Sołtys K, Wątły J, et al · · 2020 · cited 20× · PMID 32882888 · DOI 10.3390/ph13090228
Potential Prophylactic Treatments for COVID-19.
Ben-Zuk N, Dechtman ID, Henn I, Weiss L, et al · · 2021 · cited 9× · PMID 34372498 · DOI 10.3390/v13071292

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting

Other recruiting trials for Coronavirus Infections

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT05276388 — Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19) · active not recruiting
NCT04429594 — Study of the Incidence of SARS-CoV-2 Infection (COVID-19) · NA · recruiting
NCT04327570 — In-depth Immunological Investigation of COVID-19. · recruiting
NCT04318366 — COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor · recruiting

Other Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara trials

Trials by the same sponsor.

NCT03790345 — Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics · Phase 2, PHASE3 · unknown
NCT03788759 — Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia · Phase 2, PHASE3 · completed
NCT04391582 — Pediatric Burn Treatment Using Tilapia Skin as a Xenograft for Superficial-Partial Thickness Wounds · Phase 2 · completed
NCT04202289 — Use of Nile Tilapia Fish Skin as a Xenograft for Burn Treatment: Phase III Study · Phase 3 · completed
NCT03592498 — Study to Evaluate the Use of Tilapia Skin (Oreochromis Niloticus), in the Treatment of Burn Wounds · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04384458 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Last refreshed: 5 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04384458.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing